Category Archives: Cancer Treatment

Eric Lefkofsky, Going In a Whole New Direction

Eric Lefkofsky was born in Michigan in September 1969, and he graduated from the University of Michigan in Ann Arbor with honors in 1991. He later earned a law degree from University of Michigan’s Law School but decided to follow a different passion, technology. Lefkofsky’s internet career began with a company he founded called Starbelly. He later co-founded other companies such as InnerWorkings, Echo Global Logistics, Uptake, Groupon, and Tempus. He is now a wealthy, energetic entrepreneur, but he has also found time to teach at DePaul University’s Graduate School, Northwestern University’s School of Management, and Chicago’s Booth School of Business.

Tempus was co-founded in 2016 by Eric Lefkofsky who also serves as CEO. Tempus technology company the enables physicians to deliver personalized cancer care to their patients. This company is not just another project to Eric especially since his wife Elizabeth was diagnosed with breast cancer. Now Lefkofsky’s determination to make Tempus successful passionate and personal. Tempus collects and analyzes data using statistics and algorithms to give doctors additional information that allows them to develop better treatment plans for patients. The work being done at Tempus allows clinical information about a patient to be electronically compared to molecular information in real-time. This process could potentially allow cancer researchers to develop cures and treatments years sooner than previous thought.

The Lefkofsky’s have a special place in their hearts for cancer care. It is their desire to see cancer cured once and for all. As a result, they have set up the Lefkofsky Family Foundation which gives to numerous cancer researchers. The foundation donated $1 million to Northwestern University’s Robert Lurie Cancer Center, $500,000 to immunotherapy research at Stanford University, $1.2 million to cancer research at University of Michigan, and $250,000 to breast cancer research at New York’s Weill Cornell Medicine for more info about us: click here.

Eric and Elizabeth Lefkofsky are putting their resources, personally and professionally, behind defeating cancer in their lives and nearly 14.5 million other people in the United States alone.

Dr. Clay B. Siegall – Helping Cancer Patients

Dr. Clay B. Siegall is President, CEO and Chairman of the Board of Seattle Genetics. He founded the company in 1998 and has worked tirelessly to build a company that has a passion for helping cancer patients through rigorous research and drug development.


Dr. Siegall has led the company to develop ADC’s (antibody-drug coagulants) and was able to secure the first FDA approval of an ADC product in 2011. ADC’s work when combined with cancer drugs by allowing sensitive discrimination between healthy and diseased tissue in the body. The drug is called ADCETRIS and is now a global brand and used in more than 65 countries. Under his leadership the company holds multiple licenses for their ADC technology. There are more than 20 ADC products in clinical development using the Seattle Genetics technology at this time.


The one thing that lead him to make cancer patients his primary focus was watching his father suffer through cancer for 6 years. Dr. Clay Siegall knew after his father passed away that he wanted to find a way to help oncologists have more extensive tools available to them to fight cancer. He has found over the years the one thing to do over and over and recommends to others is to learn as much as you can by interacting with smart people with different expertise in many areas.


Dr. Siegall graduated from George Washington University with a Ph D in Genetics. Before founding Seattle Genetics he worked for several research programs as well as with the National Institutes of Health and Cancer. He sits on the board of several companies at this time. One of these is Ultragenyx a development stage bio pharmaceutical company.


In his position with Seattle Genetics, he works tirelessly and continually to obtain funding for development of ADC’s for cancer treatment and the urgent needs of cancer patients. Under his leadership he has led Seattle Genetics’s capital raising activities to secure millions of dollars towards clinical development of this life-saving technology.